Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India.
Puneet MisraArvind Kumar SinghBaijayantimala MishraBijayini BeheraBinod Kumar PatroGuruprasad R MedigeshiHari Shanker JoshiMohammad AhmadPradeep Kumar ChaturvediPalanivel ChinnakaliPartha HaldarMohan BairwaPradeep KharyaRahul DhodapkarRamashankar RathRandeep GuleriaSanjay Kumar RaiSitanshu Sekhar KarShashi KantSonali SarkarSubrata BaidyaSuneeta MeenaSuprakash MandalSurekha KishoreTapan MajumderVivek HadaPublished in: PloS one (2023)
Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months.